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Background and Aims: Type 2 diabetes mellitus (T2DM) is a condition defin d by 47 
hyperglycaemia, but also often presents with dyslipidaemia and suppressed HDL cholesterol. 48 
Mendelian randomization studies have suggested a causal link between low HDL cholesterol 49 
and T2DM. However, influences of gender, polymorphisms and lifestyle, all known to 50 
influence HDL cholesterol, have not been fully explored in a prospective cohort.   51 
Methods and Results: In 2001-2002, a random sample of 1514 males (18-87 years old) and 52 
1528 females (18-89 years old) were recruited in the ATTICA study. The 10-year follow-up 53 
(2011-2012) included 1485 participants. Lipids and lipoproteins levels, glucose and insulin 54 
levels were measured together with apolipoprotein A1 (apoA1) 75 G/A genotype, which is 55 
known to influence HDL-cholesterol. In total, 12.9% of the study sample developed T2DM 56 
within the 10-year follow-up period. In multivariable models, for each mg/dL increase in 57 
apoA1 levels in males, 10-year T2DM risk decreased 1.02%; while every unit increase in 58 
apoB/LDL-cholesterol ratio increased risk 4-fold. Finally, for every unit increase in 59 
triglycerides/apoA1 ratio, the risk increased 85%. HOMA-IR independently predicted T2DM 60 
10-year incidence only for carriers of GG polymorphism (all, p<0.05), but not in carriers of 61 
the GA polymorphism (all, p>0.05).  62 
Conclusion: ApoA1 was associated with decreased T2DM risk and TG/ApoA1 and 63 
apoB/LDL were associated with increased risk of T2DM, only in males. ApoA1 64 
polymorphism, which is associated with lower HDL cholesterol, influenced the predictive 65 
effects of HOMA-IR on T2DM incidence, which appeared to be moderated by physical 66 
activity, suggesting potential scope for more targeted preventative strategies.  67 
 Keywords: Lipids; HDL cholesterol; Apolipoprotein A-1; Type 2 Diabetes Risk; 68 
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In troduction  83 
Type 2 diabetes mellitus (T2DM) is a rapidly growing global health challenge [1-3]. 84 
Traditionally, management and prevention of T2DM have focused mainly on glycaemia [4, 85 
5], despite it often presenting with dyslipidaemia. It is plausible that after hyperinsulinaemia, 86 
dyslipidaemia typified by suppressed HDL cholesterol is the second most dominant feature of 87 
Metabolic Syndrome in T2DM [6]. Recently, a Mendelian randomisation study suggested a 88 
potential causal link between suppressed HDLc and T2DM risk [7]. Despite this emerging 89 
evidence, the use of lipid and lipoprotein biomarkers still mainly focuses upon predicting 90 
cardiovascular disease (CVD) risk [8, 9] including i  people with T2DM [10], with little 91 
consideration of these biomarkers when assessing T2DM risk [11].  92 
The mechanisms of how apolipoproteins and HDLc influence insulin action, a key 93 
aspect of T2DM pathogenesis has recently been explored [12]. The relationship between low 94 
HDLc and development of T2DM has been previously described [13, 14], with causality 95 
partially assessed [15] as plasma insulin increased nd plasma glucose decreased following 96 
an infusion of HDLc (including apoA1) in individuals with T2DM. The role of HDLc at 97 
physiological levels is less clear and dependent on experimental conditions. However, it 98 
appears that HDLc is potentially protective of β-cells against stressors, including glucose and 99 
oxidised LDLc [16, 17], whereas triglyceride-rich particles may be detrimental [18]. The 100 
protective effects of HDLc may be attributable to apoA1 [17]; whereas low levels of HDLc 101 
are a known risk factor [12]. 102 
There are several known modifiers of cardiovascular risk including gender, genetic 103 
factors and lifestyle which appear to act via altering an individual’s lipid profile [19], which 104 
may also influence the risk of developing T2DM. Males typically have lower HDLc 105 
compared to pre-menopausal females, leading to sugge tions that CVD risk reduction 106 
strategies should be tailored accordingly [20]. Beyond gender, a number of polymorphisms 107 
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have been identified in apolipoprotein genes. A keysingle nucleotide polymorphism in the 108 
apoA1 gene is apoA1-75 G/A, which is associated with a lower apoA1 and HDLc 109 
concentration for the GG genotype compared to the AA and a lesser extent GA [21]. The G 110 
allele has also been associated with increased myocardial infarction risk [22]. It is, therefore, 111 
logical to explore the potential moderating effects of this polymorphism in cohorts at risk of 112 
developing T2DM.  113 
Although HDLc has been proposed to be linked causally with T2DM; the link with 114 
and apoA1 and T2DM is less well defined, especially with respect to modifying effects of 115 
gender, polymorphisms or lifestyle. Therefore, this study aimed to explore potential 116 
associations of lipids, apolipoproteins, gender and poA1 polymorphisms, and risk of 117 
developing T2DM in a cohort of Greek healthy adults.  118 
 119 
Materials and methods 120 
 121 
Baseline sampling procedure (2001-2002) 122 
The ATTICA study is a large-scale, health and nutrition, prospective survey, which was 123 
carried out during 2001-2002, in the province of Attica, where Athens is a major metropolis. 124 
People with a history of CVD or other atherosclerotic diseases or having chronic viral 125 
infections or living in institutions were excluded from participation. Of the initially invited 126 
4056 individuals and after excluding those with CVD (i.e., n=117) or those having chronic 127 
viral infections (n=107), 3042 finally agreed to participate (75% participation rate); 1514 of 128 
the participants were male (aged 46±13 y; range 18-87 y), and 1528 were female (aged 45±13 129 
y; range: 18–89y). Trained personnel (i.e., cardiologists, general practitioners, dietitians and 130 
nurses) interviewed the participants, using a standard questionnaire. 131 
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More details about the aims, design and methods used in the ATTICA Study may be found 132 
elsewhere in the literature [23]. 133 
 134 
Baseline measurements 135 
Baseline assessment included information about socio-demographic characteristics (age and 136 
gender), history of diabetes, family history of diabetes, smoking status and physical activity. 137 
Smokers were defined as those who smoked at least one cigarette per day or had quitted 138 
within the previous year; the rest were defined as non-smokers. The International Physical 139 
Activity Questionnaire (IPAQ) was used to evaluate th  level of physical activity [24]. 140 
Participants were classified into two groups; either s dentary lifestyle or at least moderately 141 
active during a substantial part of the day. Weight (kg), height (m), as well as clinical 142 
characteristics, were measured using standardized procedures. Body mass index (BMI) was 143 
calculated as weight (kg) divided by standing height (in square meters).  144 
 145 
Biochemical measurements were carried out in the same l boratory that followed the criteria 146 
of the World Health Organization Lipid Reference Laboratories. Blood samples were 147 
collected from the antecubital vein between 8, and 10 am, in a sitting position after 12 hours 148 
of fasting and alcohol abstinence. Blood glucose levels (mg/dl) were measured with a 149 
Beckman Glucose Analyzer (Beckman Instruments, Fullerton, CA, USA). Serum insulin 150 
concentrations were assayed by radioimmunoassay (RIA100, Pharmacia Co., Erlangen, 151 
Germany). Insulin resistance was assessed by the calculation of the homeostasis model 152 
assessment (HOMA-R) approach (glucose in mg/dl x insul  in µU/ml / 22.5) [25]. Diagnosis 153 
of T2DM was based on the criteria of the American Diabetes Association (ADA) [26], i.e., 154 
participants who had fasting blood glucose >125 mg/dl during the examination or who 155 
reported the use of antidiabetic medication were defined as having diabetes. Serum total 156 
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cholesterol, HDL-cholesterol and triglycerides were measured using chromatographic 157 
enzymic method in a Technicon automatic analyser RA-1000 (Dade Behring, Marburg, 158 
Germany). HDL-cholesterol was determined after preci itation of the Apolipoprotein B 159 
(apoB) containing lipoproteins with dextran-magnesium-chloride. Non-HDL cholesterol was 160 
calculated by the formula: total cholesterol minus HDL cholesterol. Lipoprotein (a) was 161 
measured by a latex-enhanced turbidimetric immunoassay. LDL cholesterol calculated using 162 
the Friedewald formulae: (8) – [13] – 1/5 (triglycerides) (only for participants with 163 
triglycerides < 400 mg/dL). apoB and apoAI were measured by rate immunonephelometry. 164 
Internal quality control was in place for assessing the validity of cholesterol, triglyceride and 165 
HDL methods. The intra and inter-assay coefficients of variation of cholesterol levels did not 166 
exceed 9 %, triglycerides 4 % and HDL 4 %. Serum for the measurement of blood lipids was 167 
harvested immediately after admission.  168 
The combination of ratios used in the analysis was b ed on that published previously in 169 
association with cardiovascular risk  [27, 28]. Comparing the cholesterol marker with its 170 
corresponding apolipoprotein was selected as it has been shown to be a surrogate of function 171 
of the apolipoprotein, which would not be the case for a triglyceride to apolipoprotein ratio. 172 
 173 
DNA extraction and genotyping  174 
Genomic DNA was extracted from 2-5 mL of fresh or frozen whole blood using standard 175 
methods (Qiamp-DNA extraction kit, QIAGEN, Hilden, Germany), as described previously 176 
(29). The coding sequence variant was a G to T substit tion in exon 7 in codon 298, which 177 
alters the amino acid at this residue from Glu to Asp. Genotyping of apoA1 gene 178 
polymorphisms were performed by polymerase chain reaction (PCR) restriction length 179 
polymorphism assay previously described [29]. The location of the MspI restriction site was 180 
used to identify polymorphisms, with presence of the restriction site at -75 bp (G allele) and 181 
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at +83 bp (C allele) in the 433 bp product resulted in four fragments of 45, 66, 113 and 209 182 
bp. The absence of the restriction site at -75 bp (A allele) resulted in three fragments of 45, 183 
179 and 209 bp. The absence of the restriction site at +83 bp (T allele) created a larger 184 
fragment of 254 bp instead of two fragments of 45 and 209 bp [21]. 185 
 186 
10-year follow-up evaluation (2011-2012) 187 
During 2011-2012, the 10-year follow-up was performed. Of the n=3042 participants, 188 
n=2583 were allocated during the follow-up (85% participation rate). A detailed evaluation of 189 
the participants’ medical status was performed. Among various endpoints, development of 190 
T2DM was recorded based on diagnosis by a physician; n=210 patients diagnosed with 191 
diabetes at baseline and =1347 participants with no data regarding diabetes s atus at the 10-192 
year follow up were not included in the present analyses, yielding a working sample of 193 
n=1485 participants without diabetes at baseline, as pre ented elsewhere [30]. Further details 194 
about the baseline procedures and the 10-year follow up of the study have been presented 195 
elsewhere [31]. 196 
 197 
Statistical analysis 198 
Incidence of diabetes was calculated as the ratio of new cases (n=191) to the total number 199 
(n=1485) of participants in the follow-up. Normality for continuous variables was tested 200 
through histograms and P-P plots. Normally distribued continuous variables are presented as 201 
mean values±standard deviation, not normally distribu ed variables are presented as median 202 
(1st, 3rd quartile) and categorical variables as frequencies (r lative frequencies). Associations 203 
between categorical variables were tested using chi-squared test. Comparisons of mean 204 
values of normally distributed variables between those groups were performed using 205 
Student’s t-test, after ensuring equality of variances using Levene’s test. For non-normally 206 
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distributed variables, the Kruskal-Wallis test was applied, and next the Mann-Whitney test 207 
was performed between groups. The relative risk of developing T2DM during the 10-year 208 
period according to the participants’ baseline characteristics was estimated through the odds 209 
ratio (OR) and the 95% corresponding confidence interval, as derived from logistic 210 
regression models. This type of analysis was preferred since there were no accurate data 211 
about diabetes onset, but only diagnosis. Univariable logistic regression models were used to 212 
identify the variables that were possible independent predictors of T2DM onset but also 213 
known confounders (i.e., gender, age) were forced in the multivariable models and all of 214 
independent variables were tested for collinearity. Level of statistical significance was 215 
defined at α=0.05 and Bonferroni corrections were applied to all predictive models to 216 
counteract for multiple comparisons (in this case th  eight models). An exploratory analysis 217 
of the influence of apoA1 polymorphism on relative risk of developing T2DM during the 218 
follow-up period was also undertaken; this included an analysis of interactions with both 219 
modifiable and non-modifiable risk factors. The SPS version 23 (Statistical Package for 220 
Social Sciences, IBM Hellas SA, Greece) software was used for all statistical calculations. 221 
 222 
Results 223 
The study sample consisted of 1485 individuals (51% females) with a mean age of 45±13 224 
years (p for gender difference>0.05). Of these, 12.9% (191) developed T2DM within the 10-225 
year follow-up period, but no difference was detected between genders (p=0.574). Mean BMI 226 
at baseline of the total sample was 26.3±4.28kg/m2, with males having significantly higher 227 
mean BMI than females (27.2±3.6 vs 25.3±4.7 respectiv ly, p<0.001). Details of participant 228 




T2DM incidence was not associated with gender (p=0.574), family history of T2DM 231 
(p=0.416), sedentary lifestyle (p=0.191) and age (p=0.458). Smoking was more prevalent in 232 
males than females (p<0.001). Concerning the biomarkers relating to glucose metabolism, 233 
fasting glucose, insulin and HOMA-IR were significantly lower in females than males (all 234 
p<0.001). Baseline lipoprotein and lipid biomarkers indicated that males had significantly 235 
higher total and LDLc, Triglycerides (TG) and apoB levels, but lower HDLc and apoA1 236 
compared to females (all p<0.001), suggesting a profile highly related to gender. 237 
  238 
Several logistic regression models were applied to investigate the net effects of different 239 
biomarkers on T2DM 10-year incidence (Table 2). All models were adjusted for the same set 240 
of potential confounders and stratified by gender due to significant biomarker profile 241 
differences reported at baseline (p for interaction <0.001) (Table 1). No biomarkers were 242 
associated with T2DM 10-year risk in females, but there were significant associations for 243 
males. Specifically, for each mg/dL increase in apoA1 levels in males the 10-year T2DM risk 244 
decreased per 1.1%, independently of age, smoking, physical activity status, HOMA-IR, 245 
family history T2DM and BMI. Moreover, in males for every unit increase in apoB/LDL-246 
cholesterol ratio, the 10-year T2DM risk was 4-fold increased independent confounding risk 247 
factors used in previous models. Finally, for males, every unit increase in triglycerides/apoA1 248 
ratio, the 10-year T2DM risk increased per 85%, independent of confounding risk factors. No 249 
other biomarker or ratios were associated with T2DM 10-year risk in males. Additionally, in 250 
this cohort, it was found that HOMA-IR was the most specific independent predictor of 251 
T2DM incidence in females, with no effect of lipids or lipoprotein as observed in males.  252 
 253 
ApoA1-75G/A polymorphism data were available for 313 participants (GG: 215(68.7%) GA: 254 
89(28.4%) and AA: 9(2.9%)). The AA group was therefo  excluded due to its small number, 255 
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although representative of the population; this prevalence would negate any meaning being 256 
able to be derived. Polymorphism distribution was not i fluenced by gender (GA prevalent at 257 
29.4% of males (n=45) and 29.1% of females (n=44), p=0.958). No association was detected 258 
between polymorphism and T2DM 10-year incidence (p=0.931). However, significant 259 
interactions were observed with apolipoprotein levels (p<0.001) that led the analysis to 260 
stratification per polymorphism group (Table 3). 261 
 262 
As presented in Table 3, when the analysis was stratified per apoA175 G/A polymorphism 263 
status, none of the lipid or lipoprotein biomarkers were significantly related to T2DM 10-year 264 
risk (all p >0.05) after adjusting for confounding risk factors. Although influencing T2DM 265 
risk in the cohort as a whole (crude (Odds Ratio (OR) =2.44, 95% Confidence Interval (CI): 266 
1.94-3.07), HOMA-IR was an independent predictor of 10-year incidence of T2DM, only for 267 
GG polymorphism carriers (all p<0.05) in all presented models. Contrarily, HOMA-IR was 268 
not significantly associated with T2DM 10-year risk n any of the models for carriers of the 269 
GA polymorphism (all p>0.05). Physical activity was found to be protective against T2DM 270 
only for GG carriers (Odds Ratio (OR) =0.206, 95% Confidence Interval (CI): 0.043-0.983) 271 




This analysis investigated the influence of apolipoprotein and lipid biomarkers as predictive 276 
factors for developing T2DM during a 10-year follow-up, focusing on the potentially 277 
influencing effects of gender, apoA1 polymorphisms along with any interactions with insulin 278 
resistance (HOMA) and physical activity. This analysis has provided further evidence of how 279 
lipid profile and apolipoproteins influence the risk of developing T2DM in a Greek cohort 280 
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followed up for 10 years. Additionally, this is the first analysis to consider how gender and 281 
polymorphisms of apoA1-75 G/A may influence how lipoproteins and lipids influence 282 
ultimately risk of developing T2DM.  283 
 284 
Males were found to have significantly higher total and LDLc, TG and apoB levels, but lower 285 
HDLc and apoA1 compared to females, suggesting an influence of gender upon lipid profile. 286 
However, there were no statistically significant differences in new cases of T2DM between 287 
genders. No lipid or apolipoprotein biomarkers were associated with T2DM 10-year risk in 288 
females, but associations were significant in males. Specifically, higher apoA1 levels were 289 
seen to be protective for males, while the increase in apoB/LDL-cholesterol ratio and increase 290 
in triglycerides/apoA1 ratio were aggravating factors independent of age, smoking, physical 291 
activity status, HOMA-IR, family history of diabetes and BMI.  292 
 293 
When the analysis was stratified per apoA1-75G/A polym rphism status a known factor 294 
which influences both apoA1 and HDLc concentration, none of the biomarkers were 295 
significantly related to T2DM 10-year risk in the same multivariable models. An analysis to 296 
consider interactions between risk factors for T2DM found that HOMA-IR was an 297 
independent predictor of T2DM 10-year incidence for GG polymorphism carriers only [32]. 298 
No significant associations with T2DM 10-year risk were found in any of the models for GA 299 
polymorphism carriers. 300 
 301 
The potential differences between genders have beenlargely overlooked, in a previous study 302 
which followed up a Dutch cohort for a shorter timeframe [13]. It was noticeable that the 303 
ATTICA study sample where higher risk, having a stronger family history and greater 304 
prevalence of insulin resistance than the Dutch cohort, potentially highlighting the greater 305 
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suitability of the ATTICA cohort in studying diabetes prevention [33]. A population at higher 306 
risk of developing T2DM, by virtual of increased incidence of insulin resistance as seen in 307 
this study might explain the observation in this analysis that for apoA1 to reduce risk in 308 
males, but not in females. It might also be a reflection that the Dutch cohort data was only 309 
adjusted for glucose and not insulin, so unable to adjust for insulin resistance (HOMA-IR); a 310 
known predictive of risk of developing T2DM [34, 35]. The pattern which protective effects 311 
in males of apoA1/HDLc and increasing risk from apoB/LDLc ratios were consistent with 312 
Abbasi et al. [13] and data concerning apoB/LDLc ratio dditionally concurs with the male-313 
only cohort reported by Fizelova et al. [36]. However, this is the first cohort to suggest an 314 
effect of apoA1/triglycerides as modifying risk of developing T2DM in a long-term 315 
prospective cohort. This data provides support to the logical theory; as raised triglycerides 316 
have been previously associated with increased T2DM risk [37] and insulin resistance.  317 
  318 
The potential influencing effect of apoA1-75 G/A polymorphisms was explored in 304 319 
participants over 10-year follow up. This is believed to be the first analysis investigating any 320 
influencing effects of this polymorphism which is known to alter lipid profiles [21], with G/G 321 
carriers expressing less apoA1 and having lower levels of HDLc [32]. Although effects of the 322 
polymorphism were not seen with respect to the risk of developing T2DM, interactions were 323 
observed with HOMA-IR only being associated with increased risk of developing T2DM in 324 
those with GG polymorphism. This suggests that ident fyi g insulin resistance and then 325 
treating it in carriers of the GG polymorphism may provide a potentially more focused and 326 
effective intervention. The potential for targeted interventions for the prevention of T2DM 327 
was further highlighted by modulating effects of physical activity which reduced the risk of 328 
developing T2DM in GG carriers by 79% (OR 0.206 95% CI 0.043-0.983) but not in GA 329 
carriers (OR 0.478 95% CI 0.033-6.84) after adjusting for other confounding risk factors. 330 
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This warrants further investigation as it suggests that there is a gene-lifestyle interaction 331 
where physical activity may be more effective in reducing T2DM risk in GG carriers. The 332 
variation in response to exercise has been reported with greater response with a more 333 
favourable HDLc particle size with physical training for GG compared to GA or AA carriers 334 
[38]. However, to date, this effect has not been linked to the development of clinical 335 
conditions such as T2DM. Further research is needed to understand these mechanisms 336 
relative to risk of developing T2DM and effects of physical activity on the apolipoprotein, or 337 
the nature of HDLc particle size or its concentration. 338 
 339 
Longitudinal effects of lipid and apolipoprotein measures were previously investigated in a 340 
Dutch mixed gender cohort, where gender did not influe ce the association between lipids, 341 
apolipoprotein markers and T2DM risk. This was despit  reporting a 30% reduction in risk 342 
for males for each standard deviation shift in HDLc compared to 26% for females (OR 0.70, 343 
95% CI 0.55-0.91 and OR 0.74 CI 0.57-0.96, respectiv ly) [13]. A further Finish cohort of 344 
3686 male participants completing a mean follow-up of 5.9 years [36] found an association 345 
between worsening glycaemia and incidence of T2DM linked to the ratio of apolipoprotein 346 
and its associated lipoprotein. This further supports the theory that inadequate or altered 347 
capacity of lipids by apolipoproteins could be implicated in an increased risk of developing 348 
T2DM. As an individual’s lipid profile is influenced by insulin and glycaemia as well as 349 
potentially vice versa, therefore caution should be taken when looking to assign potential 350 
causality. In vitro work has linked apoB positively, and apoA1 negatively, to increased risk 351 
of developing T2DM [16, 17], supportive of a theory that apoA1 and HDLc are protective 352 
against the development of T2DM. However, according to our data, the nature of this effect 353 
and potential inter-individual variation appears to be further influenced by gender and apoA1-354 




Clinically, the prevention of T2DM has focused on the use of glycaemia and insulin-based 357 
markers. This has been most recently seen in the commissioning of clinical services, 358 
including NHS England National Diabetes Prevention Program, which focuses purely on 359 
changes in glycaemia and weight as outcome measures [4]. Such programs focus on a 360 
glucose centric perspective of T2DM prevention despit  evidence from a clinical perspective 361 
that the pathology should be increasingly seen as a global metabolic abnormality. The twin-362 
cycle hypothesis highlights this, identifying lipid metabolism and ectopic lipid accumulation 363 
in the pancreas and liver as key drivers of the pathology [39]. This, together with 364 
experimental models and epidemiological data suggest lipids, especially HDLc and 365 
potentially HDLc/apoA1 ratio, are predictive of developing T2DM. Additionally, in an age of 366 
personalised medicine, our data suggests that recognisin  differences in risk associated with 367 
gender and polymorphisms could be useful in targetin  interventions.  368 
 369 
Limitations 370 
Despite the importance of this study highlighting differences in gender and polymorphism for 371 
T2DM risk, there are a number of limitations. Firstly, the effect of gender and apoA1-75 372 
polymorphism on lipid and apolipoprotein were only measured at baseline examination. The 373 
number of cases for the assessment of apoA1-75 polymorphism was relatively small within 374 
the whole cohort, which suggests potential bias cannot be ruled out and if the null findings 375 
are not certain although evident. The number of participants with an AA polymorphism was 376 
so small; thus, were excluded from the analysis. An alternative approach would be to 377 
combine this group with the GA. However, this did not affect the outcome. The change in 378 
lipid and apolipoprotein concentrations over the 10-year follow up was not measured, and 379 
variation could influence risk. However, this is the same methodology that has been used in 380 
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other prospective studies and is typical in this field, making results comparable. The decision 381 
to exclude individuals with a history of cardiovascular disease could potentially hinder 382 
external validity of this analysis, as it is plausible that the dyslipidaemia associated with 383 
cardiovascular disease might be protective role in type 2 diabetes incidence. However, as 384 
there is an association with type 2 diabetes and cardiovascular disease this is unlikely, and the 385 
impact of including individuals with pre-existing cardiovascular disease would, both due to 386 
the nature of the pathology and any therapeutic interventions might have would have only 387 




Markers of lipids and apolipoproteins were associated with risk of developing T2DM only in 392 
males in this Greek cohort. Additional apoA1 polymorphisms appear to influence the 393 
predictive effect of HOMA-IR on T2DM incidence and the potential moderating role of 394 
physical activity; suggesting the potential for more targeted and individualized approaches 395 
for diabetes prevention strategies based on taking into account the influencing effects of 396 
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Table 1. Baseline lifestyle, biochemical variables and 10-year (2002-2012) incidence of diabetes, in 
the ATTICA study cohort (n=1485). 
 Males (n= 726) Females (n=759) p 
New diabetes cases, n (%) 97 (13.4) 94 (12.4) 0.574 
Age, years 46 ± 13 45 ± 14 0.458 
Ever Smoker, n (%) 456 (62.9) 346 (45.6) <0.001 
Body mass index, kg/m2 27.2 ± 3.6 25.3 ± 4.7 <0.001 
Sedentary lifestyle, n (%) 408 (56.2) 452 (59.6) 0.191 
Family history of diabetes, n (%) 135 (18.6) 156 (20.5) 0.416 
Fasting glucose, mg/dl 91 ± 13 88 ± 12 <0.001 
Fasting insulin, µU/ml 14.0 ± 3.5 11.8 ± 2.9 <0.001 
HOMA-IR 3.1 ± 0.69 2.6 ± 0.59 <0.001 
Total cholesterol, mg/dL 197 ± 41 191 ± 37 0.012 
HDL-cholesterol, mg/dL 45 ± 15 53 ± 14 <0.001 
LDL-cholesterol, mg/dL 126 ± 36 119 ± 38 0.001 
Triglycerides, mg/dL 113 (79,160) 82 (59,117) <0.001* 
ApoA1, mg/dL 148 ± 23 163 ± 27 <0.001 
ApoB, mg/dL 113 ± 29 100 ± 42 <0.001 
ApoB/ApoA1  0.781 ± 0.232  0.641 ± 0.357  <0.001 
ApoA1/HDL  3.47 ± 0.585  3.20 ± 0.762  <0.001 
ApoB/LDL  0.928 ± 0.235  0.862 ± 0.265  <0.001 
LDL/ApoA1  0.870 ± 0.283  0.755 ± 0.285  <0.001 
TG/ApoA1  0.932 ± 0.630  0.599 ± 0.391 <0.001 
TG/ApoB 1.18 ± 0.769  0.982 ± 0.850  <0.001 
Data are presented as mean values and standard deviation for normally distributed variables and 
median (1st, 3rd quartile) for not normally distributed variables (*). Categorical variables are 
presented as absolute and relative frequencies. p-values derived from independent samples test for 
the normally distributed variables and Mann-Whitney t st for the non-normally distributed variables 
(*) to test differences between genders and chi-square test was used for the categorical variables. 
HDL = high-density lipoprotein, LDL = low-density lipoprotein; HOMA-IR = homeostasis model 
assessment-insulin resistance; apoA1=apolipoprotein A-I; apoB=apolipoprotein B.  
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Table 2. Multivariable logistic regression models for various lipid biomarkers for the 10-year incidence of 
diabetes in the ATTICA study, stratified by gender (n=1485). 
 Males (n=726) Females (n=759) 
Variable OR 95% CI OR 95% CI 
Model 1: ApoB (per 1 mg/dL) 1.01 0.99-1.02  1.01 0.99-1.01 
Model 2: ApoA1 (per 1 mg/dL) 0.98 0.97-1.00 1.00 0.98-1.01 
Model 3: ApoB/ApoA1 (per 1 
unit/per 1 SD) 
3.72/1.36 0.97-14.2/0.99-1.85 1.51/1.16 0.74-3.05/0.90-1.49 
Model 4: ApoA1/HDL (per 1 
unit/per 1 SD) 
0.99/0.99 0.57-1.72/0.72-1.37 0.78/0.83 0.48-1.28/0.57-1.21 
Model 5: ApoB/LDL (per 1 
unit/per 1 SD) 
4.03/1.39* 1.05-15.5/1.01-1.90 1.68/1.15 0.53-5.21/0.85-1.55 
Model 6: LDL/ApoA1 ((per 1 
unit/per 1 SD) 
1.40/1.10 0.45-4.29/0.80-1.51 1.13/1.04 0.38-3.34/0.76-1.41 
Model 7: TG/ApoA1 (per 1 
unit/per 1 SD) 
1.85/1.47* 1.20-2.87/1.12-1.94 1.56/1.19 0.80-3.05/0.92-1.55 
Model 8: TG/ApoB (per 1 
unit/per 1 SD) 
1.17/1.13 0.86-1.57/0.89-1.42 1.07/1.06 0.81-1.39/0.84-1.32 
OR: Odds Ratio; CI: Confidence Interval; apoB: apolipoprotein B; apoA1: apolipoprotein A-I; HDL: High-
Density Lipoprotein –cholesterol; LDL: Low-Density Lipoprotein –cholesterol; TG: triglycerides. OR and CIs 
derived from multivariable binary logistic regression models adjusted for age, smoking status, physical activity 
status, HOMA-IR, family history of type 2 diabetes, BMI. (*) indicates Bonferroni corrected p-value 
significantly low. 
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Table 3. Multivariable logistic regression models for various lipid and lipoprotein biomarkers, for the 10-
year incidence of diabetes in the ATTICA study, stratified by apoA1-75G/A polymorphism (n=304). 
 GG (n=215) GA (n=89) 
Variable OR 95% CI OR 95% CI 
Model 1: ApoB (per 1 mg/dL) 1.01 0.98-1.03 1.00 0.96-1.04 
Model 2: ApoA1 (per 1 mg/dL) 0.98 0.96-1.01 0.99 0.96-1.03 
Model 3: ApoB/ApoA1 (per 1 
unit/per 1 SD) 
1.50/1.13 0.25-8.87/0.65-1.98 0.80/0.93 0.01-60.1/0.24-3.59 
Model 4: ApoA1/HDL (per 1 
unit/per 1 SD) 
0.75/0.82 0.29-1.94/0.42-1.59 0.76/0.83 0.14-4.06/0.26-2.65 
Model 5: ApoB/LDL (per 1 unit/per 
1 SD) 
1.45/1.10 0.10-19.4/0.56-2.12 0.12/0.58 0.00-159/0-3.61 
Model 6: LDL/ApoA1 (per 1 
unit/per 1 SD) 
2.10/1.24 0.11-38.4/0.53-2.87 2.11/1.24 0.02-162/0.32-4.35 
Model 7: TG/ApoA1 (per 1 unit/per 
1 SD) 
2.11/1.50 0.74-5.96/0.85-2.64 1.02/1.01 0.25-4.03/0.47-2.13 
Model 8: TG/ApoB (per 1 unit/per 1 
SD) 
1.86/1.66 0.75-4.62/0.79-3.50 2.57/2.16 0.43-15.4/0.50-9.36 
OR: Odds Ratio; CI: Confidence Interval; apoB: apolipoprotein B; apoA1: apolipoprotein A-I; HDL: High-
Density Lipoprotein –cholesterol; LDL: Low-Density Lipoprotein –cholesterol; TG: triglycerides. OR and 
CIs derived from various multivariable binary logistic regression models adjusted for gender, age, smoking 
status, physical activity status, HOMA-IR, family history of type 2 diabetes, BMI. (*) indicates Bonferroni 




• ApoA1 levels, ApoB:LDL and TG:apoA1 ratios are associated with 10-year risk of 
T2DM in males only 
• In males only a unit change in apoB: LDL cholesterol increased risk of type 2 
diabetes by 303% 
• In males only a unit change in triglycerides: apoA1 increased risk of type 2 diabetes 
by 85%  
• HOMA-IR predicted the 10-year incidence of T2DM only in apoA1 75 GG carriers 
• Physical activity may moderate the influence of HOMA-IR on T2DM incidence only 
in carriers of apoA1 75 GG. 
 
